Impact News +++ Protokoll des Earnings Call: Hydreight Technologies mit Umsatzsprung in Q3 2025, Aktie unter Druck (Investing.com DE) +++ HYDREIGHT Aktie -26,47%

ANI PHARMA Aktie

>ANI PHARMA Aktienkurs

73.25 EUR (Tradegate)

Ask: 73.5 EUR / 40 Stück

Bid: 73 EUR / 41 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ANI PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>ANI PHARMA Performance

1 Woche: +5,8%

1 Monat: -8,7%

3 Monate: -7,6%

6 Monate: +42,9%

1 Jahr: +29,6%

laufendes Jahr: +40,2%

>ANI PHARMA Aktie

Name:

ANI PHARMACEUT. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00182C1036 / A1W15D

Symbol/ Ticker:

BSFA (Frankfurt) / ANIP (NASDAQ)

Kürzel:

FRA:BSFA, ETR:BSFA, BSFA:GR, NASDAQ:ANIP

Index:

Webseite:

https://anipharmaceutical..

Profil:

Ani Pharmaceuticals Inc. is a specialty pharmaceut..
>Volltext..

Marktkapitalisierung:

1636.67 Mio. EUR

Unternehmenswert:

1943.87 Mio. EUR

Umsatz:

713.98 Mio. EUR

EBITDA:

125.06 Mio. EUR

Nettogewinn:

30.83 Mio. EUR

Gewinn je Aktie:

1.47 EUR

Schulden:

545.34 Mio. EUR

Liquide Mittel:

226.78 Mio. EUR

Operativer Cashflow:

147.41 Mio. EUR

Bargeldquote:

Umsatzwachstum:

41.25%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.098.247 USD.

Suchwörter:

ANI PHARMA, ANI PHARMACEUTICALS

Letzte Datenerhebung:

28.11.25

>ANI PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 22.46 Mio. St.

Frei handelbar: 85.21%

Leerverk. Aktien: 11.15%

Rückkaufquote: -0.18%

Mitarbeiter: 897

Umsatz/Mitarb.: 0.59 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 34.59%

Bewertung:

KGV: 50.73

KGV lG: 10.9

KUV: 2.31

KBV: 3.68

PEG-Ratio: -

EV/EBITDA: 15.54

Rentabilität:

Bruttomarge: 50.09%

Gewinnmarge: 4.32%

Operative Marge: 6.46%

Managementeffizenz:

Gesamtkaprendite: 2.65%

Eigenkaprendite: 7.83%

>ANI PHARMA Peer Group

Es sind 599 Aktien bekannt.

>ANI PHARMA Chart & Kurs - NASDAQ

>ANI PHARMA News

28.11.25 - 18:15	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
	ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival....

25.11.25 - 12:54	ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire EN)
	PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET....

21.11.25 - 16:45	Here′s How ANIP′s Rare Disease Portfolio Is Driving Top-line Growth (Zacks)
	ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales....

18.11.25 - 17:42	Jefferies Konferenz: ANI Pharmaceuticals skizziert Wachstumsstrategie für seltene Krankheiten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.11.25 - 04:02	Insiderhandel: Aufsichtsrat verkauft Aktien von ANI Pharmaceuticals im Wert von 750904 USD (Insiderkauf)
	Walsh, Patrick D. - Aufsichtsrat - Tag der Transaktion: 2025-11-13...

15.11.25 - 02:01	Insiderhandel: SVP - CORP. DEV. & STRATEGY verkauft Aktien von ANI Pharmaceuticals im Wert von 8272 USD (Insiderkauf)
	Gassert, Chad - Vorstand - Tag der Transaktion: 2025-11-13...

15.11.25 - 02:01	Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 34908 USD (Insiderkauf)
	Cook, Meredith - Vorstand - Tag der Transaktion: 2025-11-13...

15.11.25 - 02:01	Insiderhandel: SVP - CORP. DEV. & STRATEGY verkauft Aktien von ANI Pharmaceuticals im Wert von 1304163 USD (Insiderkauf)
	Gassert, Chad - Vorstand - Tag der Transaktion: 2025-11-12...

14.11.25 - 16:00	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
	ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio....

11.11.25 - 22:09	ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London (GlobeNewswire EN)
	PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, at 3:00 p.m. GMT/10:00 a.m. ET....

07.11.25 - 15:48	Earnings Call Transkript: ANI Pharmaceuticals übertrifft Q3-Prognosen 2025 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.11.25 - 15:15	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates (Zacks)
	ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

07.11.25 - 12:51	ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance (GlobeNewswire EN)
	PRINCETON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2025....

06.11.25 - 16:00	ANI Pharmaceuticals Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.10.25 - 16:45	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week′s Release (Zacks)
	ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

27.10.25 - 19:30	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
	ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter....

24.10.25 - 12:54	ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET (GlobeNewswire EN)
	PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to the market open....

16.10.25 - 12:51	ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting (GlobeNewswire EN)
	Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings...

15.10.25 - 07:01	Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 36036 USD (Insiderkauf)
	Cook, Meredith - Vorstand - Tag der Transaktion: 2025-10-13...

24.09.25 - 17:21	6 Analysts Have This To Say About ANI Pharmaceuticals (Benzinga)
	Latest Ratings for ANIP DateFirmActionFromTo Nov 2021Raymond JamesMaintainsOutperform Nov 2021Truist SecuritiesInitiates Coverage OnBuy May 2021Raymond JamesMaintainsOutperform View More Analyst Ratings for ANIP View the Latest Analyst Ratings read more...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Lebenstraum der meisten Österreicher ist, daß sie hinter dem Schreibtisch sitzen und sich an Paragraphen festhalten - das wollen wir ändern. - Dr. Josef Taus

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram